Vivimed Labs is currently trading at Rs. 109.10, up by 6.45 points or 6.28% from its previous closing of Rs. 102.65 on the BSE.
The scrip opened at Rs. 107.30 and has touched a high and low of Rs. 114.80 and Rs. 106.00 respectively. So far 1731392 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 114.80 on 28-Sep-2016 and a 52 week low of Rs. 59.64 on 29-Sep-2015.
Last one week high and low of the scrip stood at Rs. 114.80 and Rs. 81.35 respectively. The current market cap of the company is Rs. 885.13 crore.
The promoters holding in the company stood at 36.79%, while institutions and non-institutions held 2.62% and 60.59% respectively.
Investor Ashish Kacholia has acquired nearly two percentage point stake in Vivimed Labs through open market. Ashish has purchased 1.37 million equity shares representing 1.7% of total equity of the pharmaceuticals company at an average price of Rs 90.50 per share on September 27.
RBA Finance & Investment also bought 2.2 million shares or 2.74% stake in the company at price of Rs 90.5 per share. Nylim Jacob Ballas India Fund III LLC had sold part of its holding via open market. It offloaded 4.88 million shares representing 6% of total equity of Vivimed Labs at an average price of Rs 93.65 per share.
Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: